Join
Live feed
·
PRReleasevia Quantisnow
Neuphoria Therapeutics Inc. logo

Neuphoria Therapeutics Completes Target Enrollment in Phase 3 AFFIRM-1 Trial of BNC-210 in Social Anxiety Disorder (SAD)

ByQuantisnow·Wall Street's wire, on your screen.
NEUP· Neuphoria Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track NEUP (Neuphoria Therapeutics Inc.) and more on Quantisnow.